Clinical Edge Journal Scan

Early glucocorticoids bridging reduces chronic NSAID and analgesic use in early RA patients with a favorable prognosis


 

Key clinical point: Initial treatment with methotrexate (MTX) and glucocorticoids (GC) bridging reduced chronic use of the nonsteroidal anti-inflammatory drug (NSAID) and analgesics compared with MTX treatment alone in patients with early rheumatoid arthritis (eRA) considered to have a favorable prognosis.

Major finding: The number of patients with a daily chronic intake of NSAIDs was significantly lower in MTX monotherapy along with step-down GC vs. MTX monotherapy without oral GC group (14% vs. 40%; P less than .01). Even after correcting for previous chronic analgesic use and baseline pain, patients treated with MTX and step-down GCs had an 83% lower hazard of chronic use of NSAID or analgesic ( P less than .001).

Study details: Findings are from a post hoc analysis of the CareRA trial of 90 patients with eRA and favorable risk profile. Patients were randomly allocated to either MTX monotherapy without oral GC (n=47) or MTX monotherapy along with step-down GC (n=43).

Disclosures: The CareRA trial was funded by a Flemish governmental grant. All the authors declared no conflicts of interest.

Source: Pazmino S et al. RMD Open. 2021 May 24. doi: 10.1136/rmdopen-2021-001615 .

Recommended Reading

aIL-6 more effective than bDMARDs in RA with knee joint involvement
MDedge Rheumatology
RA: Obesity tied to lower odds of remission and more intensive csDMARD exposure
MDedge Rheumatology
Distinct clinical and biomechanical factors could help identify RA patients at risk for falls
MDedge Rheumatology
RA: TNFi is the most preferred therapeutic option for patients with inadequate methotrexate response
MDedge Rheumatology
Clinical Edge Commentary: RA June 2021
MDedge Rheumatology
RA: Tofacitinib modified-release 11 mg OD plus methotrexate shows promise in ORAL Shift trial
MDedge Rheumatology
Worse COVID-19 outcomes in RA patients treated with rituximab and JAKi
MDedge Rheumatology
Additional cardiovascular benefits of methotrexate in RA
MDedge Rheumatology
Tocilizumab raises risk of diverticulitis and GI perforation vs. rituximab and abatacept in RA
MDedge Rheumatology
Variation in risk profiles of early RA treatment regimens
MDedge Rheumatology